동반진단 임상 개발 시장 : 전략적 인사이트와 예측(2026-2035년)

The Companion Diagnostics Clinical Development Market is anticipated to grow at a CAGR of 12.9% from USD 2.94 billion in 2026 to USD 8.76 billion in 2035.

The companion diagnostics clinical development market is undergoing significant transformation driven by the paradigm shift toward precision medicine and the growing interdependence between therapeutic innovation and diagnostic validation. The market's evolution is characterized by the increasing recognition that targeted therapies require precise patient identification to achieve desired clinical outcomes, making companion diagnostics essential components of drug development programs. The convergence of advanced molecular technologies, including next-generation sequencing, liquid biopsy, and multi-omics platforms, is enabling more comprehensive biomarker discovery and validation. Pharmaceutical companies are expanding collaborations with diagnostic firms to address regulatory expectations and optimize trial design, creating a deeper integration of companion diagnostics across therapeutic development programs. Regulatory frameworks increasingly recognize companion diagnostics as essential components of therapeutic approvals, demanding clear demonstration of diagnostic performance. The market is witnessing significant investment in drug-diagnostic co-development, comprehensive genomic profiling, and AI-enabled biomarker discovery, positioning companion diagnostics clinical development as a critical enabler of precision medicine across global healthcare systems.

Market Drivers

• The expansion of targeted therapy development represents the primary driver for the companion diagnostics clinical development market. Targeted therapies require precise patient identification to achieve desired clinical outcomes. Demand for companion diagnostics is increasing because pharmaceutical pipelines contain a growing number of biomarker-directed treatment candidates. This shift creates pressure on sponsors to integrate diagnostic strategies during early clinical development. Drug developers are strengthening partnerships with diagnostic organizations to accelerate biomarker validation and regulatory preparation. The outcome is a deeper integration of companion diagnostics across therapeutic development programs, resulting in sustained growth in companion diagnostics clinical development utilization. The increasing adoption of precision medicine is further accelerating market growth through demand for advanced biomarker testing. Precision medicine depends on the ability to match treatments with molecular characteristics. Demand for advanced biomarker testing is rising because clinicians increasingly seek personalized treatment approaches. This transition creates challenges for conventional diagnostic methods that offer limited biological insight. Healthcare providers are incorporating molecular testing into treatment decision frameworks to improve therapeutic effectiveness. The result is sustained demand for companion diagnostic development capabilities. The growth of next-generation sequencing applications is driving demand for comprehensive biomarker testing capabilities. NGS enables comprehensive genomic profiling across multiple biomarkers. Demand for sequencing-based companion diagnostics is increasing because therapeutic development is becoming more dependent on complex molecular signatures. This complexity reduces the effectiveness of single-marker testing approaches in many clinical settings. Diagnostic developers are expanding sequencing-based platforms to support broader biomarker identification requirements. The outcome is increased adoption of NGS technologies within companion diagnostic development programs. Regulatory support for biomarker-guided therapies is strengthening market demand for clinically validated diagnostic solutions. Regulatory agencies increasingly support biomarker-driven drug development because targeted therapies can improve benefit-risk profiles. Demand for companion diagnostics is rising as approval pathways become more closely linked to validated patient selection tools. This environment increases the importance of analytical and clinical evidence generation.

Market Restraints

• Clinical validation requirements remain resource-intensive because companion diagnostics must demonstrate analytical performance and clinical utility across diverse patient populations. The rigorous evidence requirements create significant time and cost burdens for developers. Regulatory requirements vary across jurisdictions, creating development complexity and increasing timelines for global commercialization. Differences across regions create challenges for global development programs. Limited access to high-quality biomarker samples constrains validation activities and affects the speed of diagnostic development programs. The shortage of well-characterized samples creates bottlenecks in the development process. Data privacy and intellectual property concerns can create challenges for collaborative development models.

Technology and Service Type Insights

• The technology landscape is characterized by the growing importance of comprehensive genomic profiling and integrated diagnostic platforms. Demand is shifting toward NGS platforms because therapeutic pipelines increasingly target multiple genomic alterations simultaneously. This transition reduces the practicality of single-marker testing approaches for many precision medicine applications. Developers are integrating sequencing technologies into clinical development programs to improve biomarker coverage and patient identification. PCR remains important for focused biomarker detection where rapid turnaround is prioritized. IHC and ISH continue supporting protein and gene expression biomarker assessment. Digital PCR is expanding for ultra-sensitive detection applications. The segment analysis reveals that genomic biomarkers remain the dominant focus because most approved targeted therapies depend on molecular alteration detection. This focus creates limitations when disease biology extends beyond genomic drivers alone. Developers are incorporating proteomic, transcriptomic, epigenetic, and multi-omics biomarkers to improve treatment selection accuracy. Oncology represents the dominant therapeutic area because targeted therapies continue expanding across multiple tumor types. Neurology, infectious diseases, immunology, and cardiovascular diseases represent growing application areas. Demand is shifting toward blood-based testing because healthcare providers seek less invasive methods that support longitudinal monitoring. Pharmaceutical and biotechnology companies represent the leading end-user segment, with diagnostic developers and CROs expanding capabilities. The integration of AI is becoming increasingly important because biomarker development depends on the identification of clinically meaningful molecular patterns. Organizations are incorporating AI technologies to accelerate biomarker discovery and validation activities.

Competitive and Strategic Outlook

• The competitive landscape features established diagnostics and life science companies alongside specialized precision medicine and contract research organizations. Roche Diagnostics maintains a leading position because it combines global diagnostic capabilities with deep pharmaceutical integration through the broader Roche ecosystem, expanding molecular diagnostics, tissue-based testing, and sequencing collaborations to support precision medicine initiatives. QIAGEN differentiates itself through its strong biomarker testing portfolio and extensive partnerships with pharmaceutical developers, expanding molecular testing solutions, sample preparation technologies, and companion diagnostic collaborations to strengthen market presence. Agilent Technologies maintains strategic relevance through its expertise in pathology, genomics, and companion diagnostic development, enhancing biomarker testing capabilities and supporting pharmaceutical partnerships focused on precision oncology. Illumina occupies a central role because NGS increasingly supports comprehensive biomarker assessment, advancing sequencing technologies and bioinformatics capabilities to support companion diagnostic applications. Thermo Fisher Scientific leverages its broad life sciences portfolio to support companion diagnostic development across multiple stages of the value chain, expanding molecular testing technologies and regulatory support capabilities to address precision medicine needs. Abbott maintains a significant position through its molecular diagnostics expertise and global commercial infrastructure, strengthening diagnostic capabilities to address evolving precision medicine requirements. Bio-Rad contributes through its strengths in molecular biology, digital PCR, and life science research technologies. Guardant Health differentiates itself through leadership in liquid biopsy technologies. Companies are pursuing service portfolio expansion through innovation in NGS panels, liquid biopsy assays, and AI-enabled discovery tools. Strategic collaborations between diagnostic manufacturers and pharmaceutical companies are increasing, driven by the need for integrated drug-diagnostic development. Geographic expansion remains a key strategic priority, with companies targeting rapidly growing Asia Pacific and emerging markets where pharmaceutical development activity is accelerating.

Short Conclusion

• The companion diagnostics clinical development market is positioned for sustained growth driven by the convergence of targeted therapy expansion, precision medicine adoption, and regulatory support. The transition from supportive testing tools into strategic assets that directly influence therapeutic development represents a fundamental shift in precision medicine. While challenges related to clinical validation, regulatory variability, and sample access persist, strategic investments in technology, partnerships, and evidence generation are creating durable competitive advantages for market leaders. The long-term market outlook remains positive, with companion diagnostics clinical development evolving into a foundational component of precision healthcare, supporting biomarker discovery, therapeutic development, and improved patient outcomes across global healthcare systems.

Key Benefits of this Report

• Insightful Analysis: Detailed market insights across regions, customer segments, policies, socio-economic factors, consumer preferences, and industry verticals.
• Competitive Landscape: Understand strategic moves by key players to identify optimal market entry approaches.
• Market Drivers and Future Trends: Assess major growth forces and emerging developments shaping the market.
• Actionable Recommendations: Support strategic decisions to unlock new revenue streams.
• Caters to a Wide Audience: Suitable for startups, research institutions, consultants, SMEs, and large enterprises.

What Businesses Use Our Reports For

• Industry and market insights, opportunity assessment, product demand forecasting, market entry strategy, geographical expansion, capital investment decisions, regulatory analysis, new product development, and competitive intelligence.

Report Coverage

• Historical data from 2021 to 2024, Base year 2025, and Forecast years from 2026 to 2035
• Growth opportunities, challenges, supply chain outlook, regulatory framework, and trend analysis
• Competitive positioning, strategies, and market share evaluation, and trade analysis
• Revenue growth and forecast assessment across segments and regions
• Company profiling including strategies, products, financials, and key developments

TABLE OF CONTENTS

1. Executive Summary

• 1.1 Market Snapshot
• 1.2 Key Findings
• 1.3 Analyst Insights
• 1.4 Strategic Recommendations

2. Research Methodology

• 2.1 Research Design
• 2.2 Data Collection Methodology
• 2.3 Market Size Estimation
• 2.4 Forecasting Model
• 2.5 Assumptions & Limitations

3. Companion Diagnostics Clinical Development Market Overview, Size & Forecast

• 3.1 Market Definition & Scope
• 3.2 Companion Diagnostics Clinical Development Industry Overview
• 3.3 Industry Evolution
• 3.4 Key Market Trends
• 3.5 Historical Market Size Analysis (2021-2025)
• 3.6 Market Forecast Analysis (2026-2035)
• 3.7 Precision Medicine Ecosystem Analysis
• 3.8 Biomarker Discovery and Validation Landscape
• 3.9 Drug-Diagnostic Co-development Framework
• 3.10 Clinical Development Workflow for Companion Diagnostics
• 3.11 Testing Volume Analysis
• 3.12 Oncology Biomarker Development Trends
• 3.13 Companion Diagnostic Adoption Across Therapeutic Areas

4. Market Dynamics

• 4.1 Market Drivers
• 4.2 Market Restraints
• 4.3 Market Opportunities
• 4.4 Market Challenges

5. Industry Landscape

• 5.1 Industry Value Chain Analysis
• 5.2 Pricing Analysis
• 5.3 Reimbursement Landscape
• 5.4 Stakeholder Ecosystem Analysis
• 5.5 Contract Research and Development Support Landscape

6. Innovation Landscape

• 6.1 Emerging Technologies in Companion Diagnostics Development
• 6.2 Product Innovation Trends
• 6.3 Clinical Trial Analysis
• 6.4 Companion Diagnostics Pipeline Analysis
• 6.5 Next-Generation Sequencing Integration Trends
• 6.6 Liquid Biopsy Innovation Landscape
• 6.7 Multiplex Biomarker Development Trends
• 6.8 AI Integration in Biomarker Identification and Clinical Development
• 6.9 Technology Roadmap

7. Regulatory Landscape

• 7.1 Regulatory Framework
• 7.2 Approval Pathways
• 7.3 Compliance Requirements
• 7.4 Companion Diagnostic Regulatory Guidance Analysis
• 7.5 Drug-Diagnostic Co-approval Requirements

8. Companion Diagnostics Clinical Development Market Landscape Analysis

• 8.1 Analysis by Technology Platform
• 8.2 Analysis by Biomarker Type
• 8.3 Analysis by Sample Type
• 8.4 Analysis by Clinical Application
• 8.5 Analysis by Testing Methodology
• 8.6 Analysis by Development Stage
• 8.7 Analysis by Therapeutic Area
• 8.8 Analysis by Regulatory Status

9. Companion Diagnostics Clinical Development Market Segment Analysis (2021-2035)

• 9.1 By Technology Platform
  • 9.1.1 Polymerase Chain Reaction (PCR)
  • 9.1.2 Next-Generation Sequencing (NGS)
  • 9.1.3 Immunohistochemistry (IHC)
  • 9.1.4 In Situ Hybridization (ISH/FISH/CISH)
  • 9.1.5 Digital PCR
  • 9.1.6 Other Technologies
• 9.2 By Biomarker Type
  • 9.2.1 Genomic Biomarkers
  • 9.2.2 Proteomic Biomarkers
  • 9.2.3 Transcriptomic Biomarkers
  • 9.2.4 Epigenetic Biomarkers
  • 9.2.5 Multi-omics Biomarkers
• 9.3 By Sample Type
  • 9.3.1 Tissue Biopsy
  • 9.3.2 Blood-Based Samples
  • 9.3.3 Cytology Samples
  • 9.3.4 Other Sample Types
• 9.4 By Therapeutic Area
  • 9.4.1 Oncology
  • 9.4.2 Neurology
  • 9.4.3 Infectious Diseases
  • 9.4.4 Immunology and Autoimmune Disorders
  • 9.4.5 Cardiovascular Diseases
  • 9.4.6 Other Therapeutic Areas
• 9.5 By Development Phase
  • 9.5.1 Discovery and Biomarker Identification
  • 9.5.2 Analytical Validation
  • 9.5.3 Clinical Validation
  • 9.5.4 Regulatory Submission and Approval
• 9.6 By End User
  • 9.6.1 Pharmaceutical and Biotechnology Companies
  • 9.6.2 Diagnostic Developers
  • 9.6.3 Contract Research Organizations (CROs)
  • 9.6.4 Academic and Research Institutes

10. Companion Diagnostics Clinical Development Market Geographical Analysis (2021-2035)

• 10.1 North America
• 10.2 Europe
• 10.3 Asia-Pacific
• 10.4 South America
• 10.5 Middle East & Africa

11. Companion Diagnostics Clinical Development Market Country Analysis (2021-2035)

• 11.1 United States
• 11.2 Canada
• 11.3 Germany
• 11.4 United Kingdom
• 11.5 France
• 11.6 Italy
• 11.7 Spain
• 11.8 Japan
• 11.9 China
• 11.10 South Korea
• 11.11 Australia
• 11.12 India
• 11.13 Brazil

12. Competitive Landscape

• 12.1 Market Share Analysis
• 12.2 Strategic Developments
• 12.3 Mergers & Acquisitions, Partnerships & Collaborations
• 12.4 Product Launches
• 12.5 Drug-Diagnostic Partnership Analysis
• 12.6 Competitive Benchmarking

13. Company Profiles

• 13.1 Roche Diagnostics
• 13.2 QIAGEN N.V.
• 13.3 Agilent Technologies, Inc.
• 13.4 Illumina, Inc.
• 13.5 Thermo Fisher Scientific Inc.
• 13.6 Abbott Laboratories
• 13.7 Bio-Rad Laboratories, Inc.
• 13.8 Guardant Health, Inc.
• 13.9 Exact Sciences Corporation
• 13.10 Myriad Genetics, Inc.
• 13.11 Foundation Medicine, Inc.
• 13.12 Labcorp Holdings Inc.
• 13.13 NeoGenomics, Inc.
• 13.14 Sysmex Corporation
• 13.15 Danaher Corporation

14. Companion Diagnostics Clinical Development Market Commercial Forecast Analysis

• 14.1 PCR-Based Companion Diagnostics
• 14.2 NGS-Based Companion Diagnostics
• 14.3 Immunohistochemistry-Based Companion Diagnostics
• 14.4 In Situ Hybridization-Based Companion Diagnostics
• 14.5 Liquid Biopsy Companion Diagnostics
• 14.6 Comprehensive Genomic Profiling Companion Diagnostics
• 14.7 Multi-biomarker Companion Diagnostics

15. Investment & Funding Analysis

• 15.1 Venture Capital Trends
• 15.2 Government Funding
• 15.3 R&D Investments
• 15.4 Strategic Investment Activity in Precision Medicine
• 15.5 Funding Trends in Biomarker Development

16. Future Outlook

• 16.1 Key Growth Opportunities
• 16.2 Future Industry Trends
• 16.3 Future of Drug-Diagnostic Co-development
• 16.4 Evolution of Multi-omics and AI-Driven Companion Diagnostics
• 16.5 Long-Term Market Outlook (2035)